Malignant Solid NeoplasmPhase 3NCT06395441

Wisconsin Ginseng for Decreasing Cancer Related Fatigue

A Phase 3 study testing American Ginseng and Questionnaire Administration in people with Malignant Solid Neoplasm and Chronic Lymphocytic Leukemia, run by Mayo Clinic at 15 sites in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts

Official record

Search all trials

Trial summary

Who is it for?: Ages 18 years and older
Conditions the study is for: Malignant Solid Neoplasm, Chronic Lymphocytic Leukemia, Hematopoietic and Lymphatic System Neoplasm
What is being tested?: American Ginseng and Questionnaire Administration
Could I receive a placebo?: Yes, some participants may receive a placebo
How many people: 222 participants
Where: 15 sitesUnited States
Study dates: 1 Aug 2024to 30 Dec 2027
Phase: Phase 3

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Age ≥ 18 years
GROUP 1 PARTICIPANTS: Has received or is receiving treatment for a solid-organ malignancy (does not apply to Group 2)
GROUP 2 PARTICIPANTS: Diagnosis of one of the following hematologic malignancies: Chronic lymphocytic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma (NHL), multiple myeloma, or survivorship care after completion of therapy for one of the above hematologic malignancies (within 5 years of completion of therapy)
History of cancer-related fatigue as defined by an average score ≥ 4 over the past 30 days on the numeric analogue scale. Patients can answer questions orally rather than completing worksheet
Baseline control of insomnia: Insomnia ≤ 4 on Linear Analogue Scale. Patients can answer questions orally rather than completing worksheet
Baseline control of pain: Pain ≤ 4 on Linear Analogue Scale. Patients can answer questions orally rather than completing worksheet

Show all 22Show fewer

Life expectancy ≥ 6 months
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2
GROUP 1 PARTICIPANTS: The following laboratory values obtained ≤ 180 days prior to registration (does not apply to hematologic malignancies)
Hemoglobin ≥ 10.0 g/dL (patients must not have been transfused in the preceding 90 days to meet this criterion)
Alanine aminotransferase (ALT) or aspartate transaminase (AST) ≤ 3 x upper limit normal (ULN)
Creatinine ≤ 1.5 x ULN
GROUP 2 PARTICIPANTS: The following laboratory values obtained ≤ 180 days prior to registration (does not apply to solid-organ malignancies):
Hemoglobin ≥ 8.0 g/dL (patients must not have been transfused in the preceding 90 days to meet this criterion)
Platelet count ≥ 50,000 cells/mm^3
Absolute neutrophil count ≥ 1000 cells/mm^3
Alanine aminotransferase (ALT) or aspartate transaminase (AST) ≤ 3 x ULN
Creatinine ≤ 1.5 x ULN
No clinical suspicion of hypothyroidism within 180 days prior to registration (if clinical suspicion of hypothyroidism exists, a documented thyroid stimulating hormone [TSH] < 5 mIU/L is required)
Negative pregnancy test done ≤ 7 days prior to registration, for persons of childbearing potential only
Ability to complete questionnaire(s) by themselves or with assistance
Provide informed consent

Who cannot join

Any known hypersensitivity to ginseng
Currently using any other pharmacologic agents to specifically treat fatigue including psychostimulants or antidepressants. Note: Antidepressants used to treat items other than fatigue (such as hot flashes or depression) are allowed if the patient has been on a stable dose for ≥ 30 days and plan to continue such for 8 weeks. Exercise is allowed
Psychiatric disorder such as poorly controlled depression, manic depressive disorder, obsessive compulsive disorder, or schizophrenia (defined per medical history)
Use of erythropoietic agents ≤ 6 months
Uncontrolled hypertension on more than three occasions (diastolic blood pressure ≥ 100, systolic ≥ 160) measured ≤ 180 days prior to randomization
Surgery that required general anesthetic ≤ 30 days prior to randomization

Show all 20Show fewer

Malnutrition, active infection, severe depression, or significant pulmonary disease and cardiovascular disease (as determined by the attending clinician), as they could impact fatigue
Use of any over the counter herbal/dietary supplement marketed for fatigue or energy (for example, products containing any type of ginseng, Rhodiola rosea, guarana, or anything called an "adaptogen")
Currently using an antidiabetic drug, warfarin or monamine oxide inhibitor
Examples of antidiabetic drugs include: Insulin, sulfonylureas, sodium-glucose co-transporter subtype 2 (SGLT2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, thiazolidinediones, glucagon-like peptide 1 (GLP-1) receptor agonists/dual incretin agonists, and related agents
Treating provider anticipates a change to the anti-cancer treatment program in the next 8 weeks (i.e., the intervention period)
Any of the following because this study involves an investigational agent whose genotoxic, mutagenic, and teratogenic effects on the developing fetus and newborn are unknown:
Pregnant persons
Nursing persons
Persons of childbearing potential who are unwilling to employ adequate contraception. (e.g., hormonal methods, barrier methods, intrauterine device, abstinence)
GROUP 2 PARTICIPANTS: Patients who have been hospitalized (> 24 hours) in the previous 2 months or who will require hospitalization (for anti-cancer therapy) within the next 3 months
GROUP 2 PARTICIPANTS: Prior allogeneic transplant
GROUP 2 PARTICIPANTS: Chimeric antigen receptor T cell (CAR-T), or autologous transplant within the last 180 days
GROUP 2 PARTICIPANTS: T-cell engager initiation within the last 3 months (patients on stable maintenance dosing are permitted)
GROUP 2 PARTICIPANTS: Enrolled in another interventional clinical trial

Trial locations and contacts

15 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Clinical Trials Referral Office contact

855-776-0015

mayocliniccancerstudies@mayo.edu

City, postcode or hospital

Sites recruiting now only

15 sites in 1 country

United States15 sites, 14 recruiting

Mayo Clinic Health System in Albert Lea
Albert Lea, Minnesota, 56007
Clinical Trials Referral Office, 855-776-0015, mayocliniccancerstudies@mayo.edu
Danielle Mutschler, 507-377-4817, Mutschler.Danielle@mayo.edu
Recruiting
Sanford Joe Lueken Cancer Center
Bemidji, Minnesota, 56601
Jarrett Failing, MD, 612-624-2620, ccinfo@umn.edu
Jarrett Failing, MD
Recruiting
Essentia Health Saint Joseph's Medical Center
Brainerd, Minnesota, 56401
Bret Friday, MD, 612-624-2620, ccinfo@umn.edu
Bret Friday, MD
Recruiting
Essentia Health Deer River Clinic
Deer River, Minnesota, 56636
Bret Friday, MD, 612-624-2620, ccinfo@umn.edu
Bret Friday, MD
Recruiting
Essentia Health St. Mary's Detroit Lakes Clinic
Detroit Lakes, Minnesota, 56501
Bret Friday, MD, 612-624-2620, ccinfo@umn.edu
Bret Friday, MD
Recruiting
Essentia Health Cancer Center
Duluth, Minnesota, 55805
Bret Friday, MD, 218-786-3625, ccinfo@umn.edu
Bret Friday, MD
Recruiting
Essentia Health Fosston
Fosston, Minnesota, 56542
Bret Friday, MD, 612-624-2620, ccinfo@umn.edu
Bret 1 Friday, MD
Recruiting
Essentia Health Hibbing Clinic
Hibbing, Minnesota, 55746
Bret Friday, MD, 612-624-2620, ccinfo@umn.edu
Bret Friday, MD
Recruiting
Mayo Clinic Health System-Mankato
Mankato, Minnesota, 56001
Clinical Trials Referral Office, 855-776-0015, mayocliniccancerstudies@mayo.edu
Jenna Ziegler, 507-594-7479, Ziegler.Jenna@mayo.edu
Recruiting
MMCORC CentraCare Monticello Cancer Center
Monticello, Minnesota, 55362
Completed
Mayo Clinic in Rochester
Rochester, Minnesota, 55905
Clinical Trials Referral Office, 855-776-0015, mayocliniccancerstudies@mayo.edu
Daniel S. Childs, M.D.
Recruiting
Essentia Health Sandstone
Sandstone, Minnesota, 55072
Bret Friday, MD, 612-624-2620, ccinfo@umn.edu
Bret Friday, MD
Recruiting
Sanford Thief River Falls Medical Center
Thief River Falls, Minnesota, 56701
Amit Panwalkar, MD, 612-624-2620, ccinfo@umn.edu
Amit Panwalkar, MD
Recruiting
Essentia Health Virginia Clinic
Virginia, Minnesota, 55792
Bret Friday, MD, 612-624-2620, ccinfo@umn.edu
Bret Friday, MD
Recruiting
Sanford Worthington Medical Center
Worthington, Minnesota, 56187
Jonathan Bleeker, MD, jonathan.bleeker@sanfordhealth.org
Jonathan Bleeker, MD
Recruiting

Other trials in United States

About this study

Official title: Phase III Study of Ginseng for Cancer Related Fatigue

This phase III trial compares the effect of Wisconsin ginseng (panax quinquefolius) to placebo in patients with cancer that suffer from significant fatigue. Fatigue is among the most challenging symptoms to manage in patients with cancer, both on or off active treatment. This symptom complex meaningfully contributes to psychosocial distress, healthcare costs, and it also interferes with the delivery of anticancer therapies. American ginseng (Western ginseng) appears to be a promising appearing agent for treating cancer related fatigue. Western ginseng may reduce cancer-related fatigue.

Read the detailed description

PRIMARY OBJECTIVE:

To determine the efficacy of ginseng as assessed by a single item measure of fatigue at 8 weeks.

SECONDARY OBJECTIVES:

To estimate changes in fatigue via the single item measure of fatigue from baseline to week 4, the Global Impression of Change at week 4 and 8, and the Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-Fatigue) at week 4 and 8.

II. To evaluate the frequency and severity of toxicity as reported by the patient on the Ginseng Symptom Experience Diary where patients rate (on a 0 to 10 scale) their toxicities experienced while on study.

OUTLINE: Patients are randomized to 1 of 2 groups.

GROUP I: Patients receive Western ginseng orally (PO) twice daily (BID) on days 1-56.

GROUP II: Patients receive placebo PO BID on days 1-56.

Conditions: Malignant Solid Neoplasm, Chronic Lymphocytic Leukemia, Hematopoietic and Lymphatic System Neoplasm, Hodgkin Lymphoma, Multiple Myeloma, Non-Hodgkin Lymphoma
Being tested: American Ginseng, Placebo Administration, Questionnaire Administration
Medical subject headings: Leukemia, Lymphocytic, Chronic, B-Cell, Hodgkin Disease, Multiple Myeloma, Lymphoma, Non-Hodgkin

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

American GinsengDietary supplement
Also called Ginseng, Ginseng Root, Panax quinquifolius
Given PO
Placebo AdministrationDrug
Given PO
Questionnaire AdministrationOther
Ancillary studies

Study groups in NCT06395441
Study group	Role	What they receive
Group I (Western ginseng)	Experimental	Patients receive Western ginseng PO BID on days 1-56. Treatment continues in the absence of disease progression or unacceptable toxicity. Receives: Dietary Supplement: American Ginseng; Other: Questionnaire Administration
Group II (placebo)	Placebo comparator	Patients receive placebo PO BID on days 1-56. Treatment continues in the absence of disease progression or unacceptable toxicity. Receives: Drug: Placebo Administration; Other: Questionnaire Administration

What is being measured

The primary outcome is the main question the study is designed to answer.

Change in fatigue at 8 weeks
Will be measured by the Linear Analog Scale for Fatigue, a single-item questionnaire rating fatigue over the pats week on a scale of 0-10 where 0=no fatigue at all and 10=fatigue as bad as it can be.
Measured: Baseline to 8 weeks

Secondary outcomes (3)

Percentage of patients who perceive moderate to very much better fatigue
Will be measured by the Global Impression of Change scale, which consists of 3 questions answered on a scale of -3 (very much worse) to 3 (very much better), one question as to whether the participants thought they were receiving the intervention (ginseng) or placebo, and one question related to satisfaction with the effect of the treatment on their fatigue (yes/no).
Measured: 4 weeks, 8 weeks
Change in Fatigue - FACIT-Fatigue
Will be measured by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Scale, which consists of 13 questions answered on a scale of 0-4 where 0=not at all and 4=very much.
Measured: 4 weeks, 8 weeks
Patient-reported Toxicities - Ginseng Symptom Experience Diary
Will be measured using the Ginseng Symptom Experience Diary, where patients rate toxicities experienced while on study. The diary asks patients to rate a list of 7 symptoms over the past week on a scale of 0 (none at all) to 10 (as bad as it can be), with higher scores indicating greater severity of symptoms.
Measured: Up to 8 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

1 Aug 202430 Dec 2027

First posted2 May 2024
Study start1 Aug 2024
Primary completion30 Dec 2027 (estimated)
Study completion30 Dec 2027 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for Malignant Solid NeoplasmStudies of the same condition, open and under way.
More trials run by Mayo ClinicThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 3
Primary purpose: Supportive care
Allocation: Randomised
Intervention model: Parallel groups
Masking: Double blind
Who is masked: Participant, Investigator
Enrolment: 222 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT06395441
Sponsor's protocol ID: MC231004
Other IDs: 23-012122, MNCCTN037
Status last verified: Oct 2026
First submitted: 29 Apr 2024
Last updated: 20 Oct 2026
Results posted: No
Data monitoring committee: Yes
FDA-regulated drug: Yes
FDA-regulated device: No
Individual data sharing: No